Fingerprint Dive into the research topics of 'Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial'. Together they form a unique fingerprint.
- Sort by
- Weight
- Alphabetically